Check Hep C: A Community-Based Approach to Hepatitis C Diagnosis and Linkage to Care in High-Risk Populations
Overview
Affiliations
Context: In New York City (NYC), an estimated 146 500 people, or 2.4% of the adult population, have chronic hepatitis C virus (HCV) infection and half may be unaware of their infection. Despite a 2014 state law requiring health care providers to screen for HCV infection in primary care settings, many high-risk HCV-positive persons are not, and a large proportion of those screened do not receive RNA testing to confirm infection, or antiviral therapies.
Objective: The NYC Department of Health's Check Hep C program was designed to increase hepatitis C diagnosis and improve linkage to care at community-based organizations.
Design: Coordinated, evidence-based practices were implemented at 12 sites, including HCV antibody testing, immediate blood draw for RNA testing, and patient navigation to clinical services.
Results: From May 2012 through April 2013, a total of 4751 individuals were tested for HCV infection and 880 (19%) were antibody-positive. Of antibody-positive participants, 678 (77%) had an RNA test, and of those, 512 (76%) had current infection. Of all participants, 1901 were born between 1945 and 1965, and of those, 201 (11%) were RNA-positive. Ever having injected drugs was the strongest risk factor for HCV infection (40% vs 3%; adjusted odds ratio [AOR] = 19.1), followed by a history of incarceration (18% vs 4%; AOR = 2.2). Of the participants with current infection, 85% attended at least 1 follow-up hepatitis C medical appointment. Fourteen patients initiated hepatitis C treatment at a Check Hep C site and 6 initiators achieved cure.
Conclusion: The community-based model successfully identified persons with HCV infection and linked a large proportion to care. The small number of patients initiating hepatitis C treatment in the program identified the need for patient navigation in high-risk populations. Results can be used to inform screening and linkage-to-care strategies and to support the execution of hepatitis C screening recommendations.
Bhatraju E, Kennedy D, Gojic A, Iles-Shih M, Merrill J, Samet J Addict Sci Clin Pract. 2025; 20(1):6.
PMID: 39881397 PMC: 11780921. DOI: 10.1186/s13722-025-00538-1.
Thompson L, Plitt S, Zhuo R, Charlton C Can Liver J. 2024; 7(2):273-285.
PMID: 38746866 PMC: 11089476. DOI: 10.3138/canlivj-2023-0027.
Essex W, Mera J, Comiford A, Winters A, Feder M J Community Health. 2023; 48(6):982-993.
PMID: 37531046 PMC: 10558369. DOI: 10.1007/s10900-023-01264-y.
Corona-Mata D, Rivero-Juarez A, Camacho A, Ruiz-Torres L, Ruiz-Caceres I, de la Fuente Darder B Front Public Health. 2023; 11:1092960.
PMID: 36817894 PMC: 9932806. DOI: 10.3389/fpubh.2023.1092960.
Closing the hepatitis C treatment gap: United States strategies to improve retention in care.
Jones A, Briones C, Tran T, Moreno-Walton L, Kissinger P J Viral Hepat. 2022; 29(8):588-595.
PMID: 35545901 PMC: 9276641. DOI: 10.1111/jvh.13685.